Enzymedica, Inc., a manufacturer of enzyme focused supplements is excited to announce the appointment of Scott Sensenbrenner to the position of Chief Executive Officer.
Sensenbrenner is an accomplished leader, with a track record of working with some of the industry’s leading nutritional companies. He brings a great mix of leadership, inspiration, operational experience and a passion for customer care. His background includes working for Enzymatic Therapy where he was instrumental in helping them build the markets for several leading products such as GS500, IP-6, Esberitox, St. John's Wort, and Remifemin.
In 2001, Sensenbrenner joined Perrigo as Group Director of their Nutrition Division, one of the largest OTC/nutritional organizations in the world with over $2 Billion in sales. Most recently, Sensenbrenner served as Vice President of Marketing & Sales for Thorne Research a leading manufacturer and marketer of therapeutic supplements sold exclusively to health care practitioners.
As Chief Executive Officer, Sensenbrenner's responsibility will be to build upon Enzymedica's solid foundation of leading the industry with innovative enzyme based dietary supplements.
Tom Bohager, Enzymedica's Founder and Operating Chairman will remain active in key decisions, sharing jointly with Sensenbrenner in the development of short and long range strategies for the company.
To learn more about Enzymedica, visit www.enzymedica.com.
About Enzymedica, Inc.:
Florida-based Enzymedica, Inc., was founded in 1998 to offer consumers targeted enzyme products that address digestion issues, food allergies and intolerances, cardiovascular issues, immune function and inflammation. The exclusive Enzymedica Thera-blend™ process combines different strains of each major enzyme to work more broadly in the digestive tract and throughout the entire body. Enzymedica's products are made from only the highest quality plant and plant-based enzymes.